Cargando…
Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
BACKGROUND: Gemcitabine plus platinum is the standard of care first-line treatment for advanced biliary tract cancers (BTC). There is no established second-line therapy, and retrospective reviews report median progression-free survival (PFS) less than 3 mo on second-line therapy. 5-Fluorouracil plus...
Autores principales: | Mizrahi, Jonathan D, Gunchick, Valerie, Mody, Kabir, Xiao, Lianchun, Surapaneni, Phanikeerthi, Shroff, Rachna T, Sahai, Vaibhav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960075/ https://www.ncbi.nlm.nih.gov/pubmed/31966916 http://dx.doi.org/10.4251/wjgo.v12.i1.83 |
Ejemplares similares
-
FOLFIRI as second-line treatment of metastatic biliary tract cancer patients
por: Caparica, Rafael, et al.
Publicado: (2019) -
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy
por: Gunchick, Valerie, et al.
Publicado: (2023) -
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
por: Devaux, Madeline, et al.
Publicado: (2019) -
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018) -
1 Analysis of dietary intake and biliary tract cancer risk in 638,860 Chinese and European adults in three cohort studies
por: Gunchick, Valerie, et al.
Publicado: (2023)